European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2026, 10:00 (CEST) to 23 September 2026, 12:00 (CEST)

Submitted by Anonymous (not verified) on 23 September 2026 - 8:15

Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - September 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 23 September 2026, 10:00 (CEST) to 23 September 2026, 12:00 (CEST)

Human medicines European public assessment report (EPAR): mCombriax, influenza mRNA vaccine,COVID-19 mRNA vaccine, Date of authorisation: 20/04/2026, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 16:20

Human medicines European public assessment report (EPAR): mCombriax, influenza mRNA vaccine,COVID-19 mRNA vaccine, Date of authorisation: 20/04/2026, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 49, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 16:12

Human medicines European public assessment report (EPAR): Pegasys, peginterferon alfa-2a, Date of authorisation: 20/06/2002, Revision: 49, Status: Authorised

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Date of authorisation: 09/12/2009, Revision: 51, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:52

Human medicines European public assessment report (EPAR): Prevenar 13, pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), Date of authorisation: 09/12/2009, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 26, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:45

Human medicines European public assessment report (EPAR): Blincyto, blinatumomab, Date of authorisation: 23/11/2015, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 3, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:36

Human medicines European public assessment report (EPAR): Xbonzy, denosumab, Date of authorisation: 17/11/2025, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 24, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:25

Human medicines European public assessment report (EPAR): Leflunomide Zentiva (previously Leflunomide Winthrop), leflunomide, Date of authorisation: 08/01/2010, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Date of authorisation: 30/09/2008, Revision: 43, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:22

Human medicines European public assessment report (EPAR): Xarelto, rivaroxaban, Date of authorisation: 30/09/2008, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Date of authorisation: 18/09/2026, Status: Authorised

Submitted by Anonymous (not verified) on 22 September 2026 - 15:15

Human medicines European public assessment report (EPAR): Icotyde, icotrokinra hydrochloride, Date of authorisation: 18/09/2026, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness